Luo X - Search Results

1

Efficacy of oral irinotecan against neuroblastoma xenografts.

Thompson J, Zamboni WC, Cheshire PJ, Richmond L, Luo X, Houghton JA, Stewart CF, Houghton PJ. Thompson J, et al. Among authors: luo x. Anticancer Drugs. 1997 Apr;8(4):313-22. doi: 10.1097/00001813-199704000-00002. Anticancer Drugs. 1997. PMID: 9180383

2

Schedule-dependent efficacy of camptothecins in models of human cancer.

Houghton PJ, Stewart CF, Zamboni WC, Thompson J, Luo X, Danks MK, Houghton JA. Houghton PJ, et al. Among authors: luo x. Ann N Y Acad Sci. 1996 Dec 13;803:188-201. doi: 10.1111/j.1749-6632.1996.tb26388.x. Ann N Y Acad Sci. 1996. PMID: 8993512 No abstract available.

3

Probenecid alters topotecan systemic and renal disposition by inhibiting renal tubular secretion.

Zamboni WC, Houghton PJ, Johnson RK, Hulstein JL, Crom WR, Cheshire PJ, Hanna SK, Richmond LB, Luo X, Stewart CF. Zamboni WC, et al. Among authors: luo x. J Pharmacol Exp Ther. 1998 Jan;284(1):89-94. J Pharmacol Exp Ther. 1998. PMID: 9435165

4

Studies of the efficacy and pharmacology of irinotecan against human colon tumor xenograft models.

Zamboni WC, Stewart CF, Cheshire PJ, Richmond LB, Hanna SK, Luo X, Poquette C, McGovren JP, Houghton JA, Houghton PJ. Zamboni WC, et al. Among authors: luo x. Clin Cancer Res. 1998 Mar;4(3):743-53. Clin Cancer Res. 1998. PMID: 9533544

5

Relationship between topotecan systemic exposure and tumor response in human neuroblastoma xenografts.

Zamboni WC, Stewart CF, Thompson J, Santana VM, Cheshire PJ, Richmond LB, Luo X, Poquette C, Houghton JA, Houghton PJ. Zamboni WC, et al. Among authors: luo x. J Natl Cancer Inst. 1998 Apr 1;90(7):505-11. doi: 10.1093/jnci/90.7.505. J Natl Cancer Inst. 1998. PMID: 9539245

6

Efficacy of systemic administration of irinotecan against neuroblastoma xenografts.

Thompson J, Zamboni WC, Cheshire PJ, Lutz L, Luo X, Li Y, Houghton JA, Stewart CF, Houghton PJ. Thompson J, et al. Among authors: luo x. Clin Cancer Res. 1997 Mar;3(3):423-31. Clin Cancer Res. 1997. PMID: 9815701

7

Evaluation of irinotecan in combination with 5-fluorouracil or etoposide in xenograft models of colon adenocarcinoma and rhabdomyosarcoma.

Houghton JA, Cheshire PJ, Hallman JD 2nd, Lutz L, Luo X, Li Y, Houghton PJ. Houghton JA, et al. Among authors: luo x. Clin Cancer Res. 1996 Jan;2(1):107-18. Clin Cancer Res. 1996. PMID: 9816097

8

P-glycoprotein expression at diagnosis may not be a primary mechanism of therapeutic failure in childhood rhabdomyosarcoma.

Kuttesch JF, Parham DM, Luo X, Meyer WH, Bowman L, Shapiro DN, Pappo AS, Crist WM, Beck WT, Houghton PJ. Kuttesch JF, et al. Among authors: luo x. J Clin Oncol. 1996 Mar;14(3):886-900. doi: 10.1200/JCO.1996.14.3.886. J Clin Oncol. 1996. PMID: 8622037

9

A phase I study of sulofenur in refractory pediatric malignant solid tumors.

Pratt CB, Bowman LC, Marina N, Pappo A, Avery L, Luo X, Meyer WH. Pratt CB, et al. Among authors: luo x. Invest New Drugs. 1995;13(1):63-6. doi: 10.1007/BF02614222. Invest New Drugs. 1995. PMID: 7499110 Clinical Trial.

10

Pharmacokinetics and pharmacodynamics of 21-day continuous oral etoposide in pediatric patients with solid tumors.

Sonnichsen DS, Ribeiro RC, Luo X, Mathew P, Relling MV. Sonnichsen DS, et al. Among authors: luo x. Clin Pharmacol Ther. 1995 Jul;58(1):99-107. doi: 10.1016/0009-9236(95)90077-2. Clin Pharmacol Ther. 1995. PMID: 7628187 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

19,867 results

Search Page

Filters